#zepbound

17 articles tagged #zepbound.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

#2026 4#503a 1#503b 2#FDA 1#alternatives 1#ban 1#before-and-after 1#beginners 2#brand-name 3#bridge-program 1#cagrilintide 1#cagrisema 1#comparison 2#compounded 8#compounded-semaglutide 1#compounded-tirzepatide 1#compounding-ban 1#copay 1#cost 13#coupon 1#coverage 1#diabetes 1#diet 1#dosage 1#eli-lilly 3#enforcement 1#enrollment 1#fact-check 1#fda 3#fda-approval 1#flat-rate 1#foundayo 7#framework 1#glp-1-patches 1#glucose-monitors 1#guide 1#hhs 1#hims 1#how-to-get 1#injectable 7#injection 1#insulin-resistance 1#insurance 11#ivy-rx 1#ivyrx 1#legality 1#liraglutide 1#medicaid 1#medicare 5#mounjaro 6#news 2#novo-nordisk 2#oral-glp1 6#oral-semaglutide 1#orforglipron 4#ozempic 7#pcos 1#pill 1#pipeline 1#policy 1#prior-authorization 2#regulation 2#results 1#rfk 1#ro 1#safety 3#savings-card 1#schedule 1#semaglutide 19#shortage 1#side-effects 9#supplements 1#surmount 2#surmount-5 1#telehealth-enforcement 1#telehealth-review 1#timeline 1#tirzepatide 18#type-2-diabetes 1#warning-letters 1#wegovy 16#wegovy-hd 1#wegovy-pill 3#weight-loss 26#without-insurance 1#zepbound 17
Editorial lifestyle photograph illustrating Medicare Part D GLP-1 coverage in 2026
GuideCost & InsuranceJune 30, 2026• 18 min read

Medicare GLP-1 Coverage July 2026: $50/mo Wegovy + Zepbound Bridge Program Guide

Updated June 30, 2026 (launch day eve): Medicare Part D covers Foundayo, Wegovy, and Zepbound for weight loss starting July 1, 2026 via the Medicare GLP-1 Bridge program. Flat $50/month copay. 3.4 million beneficiaries eligible. Both oral pills (Foundayo and Wegovy tablet) are covered. Runs through Dec 31, 2027 (BALANCE Model Part D launch delayed indefinitely as of April 2026; Bridge extended to fill the gap).

Editorial still-life illustrating two parallel paths, a calm side-by-side comparison
AnalysisComparisonsJune 24, 2026• 11 min read

Mounjaro vs Ozempic (2026): The Honest Head-to-Head Your Doctor Won't Have Time For

Mounjaro (tirzepatide) and Ozempic (semaglutide) are both FDA-approved only for type 2 diabetes, neither is approved for weight loss (that's their sister brands, Zepbound and Wegovy). In the first head-to-head trial, SURMOUNT-5, tirzepatide beat semaglutide for weight loss (−20.2% vs −13.7% over 72 weeks), and in SURPASS-2 tirzepatide cut A1C more. But Ozempic's semaglutide has the SELECT cardiovascular outcome data Mounjaro doesn't. Here's the data-driven breakdown, plus the cheaper cash-pay paths if your insurance says no.

Editorial still-life illustrating the Medicare GLP-1 Bridge enrollment process and access to weight-loss medication
GuideCost & InsuranceJune 11, 2026• 16 min read

Medicare GLP-1 Bridge Enrollment Guide 2026: $50 Copay for Foundayo, Wegovy & Zepbound

Updated June 11, 2026: CMS released the official prior authorization request form (cms.gov/glp-1-bridge.pdf, June 8) revealing a key eligibility nuance, beneficiaries with OSA, MASH, T2D, or established CVD are NOT eligible for the Bridge (they route through regular Part D instead). The Bridge is for weight-management-only patients. Four drugs covered at a $50/month flat copay: Foundayo, Wegovy injection, Wegovy oral tablet, and Zepbound KwikPen. Prior auth via Humana/LI NET; requests not processed before July 1. Complete enrollment guide.

Editorial still-life illustrating retatrutide, a Phase 3 triple-agonist weight loss drug
AnalysisNews & PipelineJune 10, 2026• 11 min read

Retatrutide TRIUMPH-1 Results (May 2026): 30.3% Weight Loss, Phase 3 Primary Trial

Updated June 10, 2026 (ADA 2026 full dataset): Retatrutide Phase 3 program complete. Obesity (TRIUMPH-1): 28.3% weight loss at 80 weeks, 30.3% at 104 weeks, 65.3% achieved BMI <30. T2D (TRANSCEND-T2D-1): A1C −2.0%, weight −16.8%. Comorbidities (ADA June 2026): TRIUMPH-4 knee OA, WOMAC pain score −4.0 points (≈75% reduction) vs −2.1 placebo; 14.1% pain-free on 9mg vs 4.2% placebo. TRIUMPH-1 OSA secondary: 60.6% AHI reduction (58.6 → ~23 events/hr). NDA expected Q4 2026.

Editorial lifestyle photograph accompanying a tirzepatide dosage chart and weight loss schedule guide
GuideGuidesMay 7, 2026• 9 min read

Tirzepatide Dosage Chart for Weight Loss 2026: Complete Schedule (Zepbound, Mounjaro & Compounded)

Verified May 2026: Tirzepatide starts at 2.5 mg once weekly (non-therapeutic starter dose), escalates by 2.5 mg every 4 weeks to a maximum of 15 mg once weekly. Full escalation takes 20 weeks. At 72 weeks, the 15 mg dose produced 20.9% body weight loss in SURMOUNT-1, equivalent to roughly 47 lbs for a 225-lb person. The 5 mg and 10 mg doses are also valid long-term maintenance doses (15% and 19.5% weight loss respectively). Same dosing schedule applies to Zepbound, Mounjaro, and compounded tirzepatide.

Editorial photograph illustrating a comparison of Zepbound and Mounjaro tirzepatide medications
AnalysisComparisonsApril 22, 2026• 12 min read

Zepbound vs Mounjaro (April 2026): Same Drug, Different Labels, Which Is Right for You?

Verified April 2026: Zepbound and Mounjaro are the exact same drug (tirzepatide) at the same doses. Mounjaro was FDA-approved May 2022 for Type 2 diabetes. Zepbound was FDA-approved November 2023 for chronic weight management and December 2024 for obstructive sleep apnea. List price is ~$1,087/mo for both; with commercial insurance + savings cards both drop to $25/mo (max $1,950/yr). The real differences: which one your insurance covers, what the FDA label allows, and Zepbound's LillyDirect self-pay vials at $299-$449/mo, a program Mounjaro does not offer.

Editorial lifestyle still-life accompanying a guide to Zepbound side effects and management
GuideSide Effects & SafetyApril 20, 2026• 10 min read

Zepbound Side Effects (2026): Nausea 29%, Diarrhea 23%, Vomiting 13%, Full Guide with SURMOUNT Trial Data

Verified April 2026: Zepbound (tirzepatide) side effects from the SURMOUNT clinical trials, nausea affects 24-29% of patients (vs 8% placebo), diarrhea 19-23%, vomiting 8-13%. Only 4.3% discontinued at the highest dose. GI symptoms peak during dose escalation and resolve within 4-8 weeks for most patients. Full breakdown by dose, timeline, management strategies, and when to call your doctor.

Editorial lifestyle photograph illustrating a 2026 GLP-1 cost guide
AnalysisCost & InsuranceApril 17, 2026• 11 min read

GLP-1 Cost 2026: Wegovy, Zepbound & Ozempic Prices ($25–$1,350/mo)

How much do GLP-1 medications cost in 2026? Wegovy, Zepbound, Ozempic, Mounjaro & Foundayo range from $25–$1,350/month. With insurance + savings card: $25/mo. Without insurance: $146/mo compounded sema (Yucca Health), $149/mo Foundayo pill, $299–449/mo brand injectable (LillyDirect, NovoCare). Medicare: $50/mo starting July 2026. Prices verified April 17, 2026 across 48 providers.

Editorial lifestyle photograph illustrating a beginner guide to GLP-1 weight loss medications
GuideGuidesApril 13, 2026• 12 min read

GLP-1 Receptor Agonists for Weight Loss 2026: FDA-Approved Options, Cost & Prescription Guide

FDA-approved GLP-1 receptor agonists for weight loss, 2026 guide. Eligibility: BMI 30+ (or 27+ with comorbidity). Semaglutide produces 14.9% weight loss (STEP-1), tirzepatide 20.9% (SURMOUNT-1). Cost: $25-$349/mo via telehealth. Complete 5-step prescription process with verified provider pricing. Options: Foundayo (orforglipron), oral Wegovy, Zepbound, and injectable semaglutide.

Featured Partners

Four affiliate partners we feature, we may earn a commission.

Yucca Health

7.7/10
$146/mo·Compounded
Visit Yucca HealthReview

Gala

7.2/10
$149/mo·Brand & Compounded
Visit GalaReview

TrimRx

7.8/10
$149/mo·Compounded
Visit TrimRxReview

SkinnyRx

7.3/10
$199/mo·Compounded
Visit SkinnyRxReview

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.